https://www.selleckchem.com/pr....oducts/compstatin.ht
Mean peak expiratory flow rate (PEFR) significantly increased from initial to final smTAP trials (p less then 0.001). Fourteen participants increased PEFR, with gains of more than 10% in 11 participants. Variability of PEFR (p = 0.01) and cough expired volume (p = 0.01) significantly decreased across smTAP trials. This study is the first to demonstrate the ability of people with PSP to immediately upregulate cough function, providing preliminary support for the feasibility of cough rehabilitation in this population with this novel
Like
Comment
Share
